Forbes contributors publish independent expert analyses and insights. Kim Elsesser covers issues that impact women in the workplace. Organizations regularly use non-disclosure agreements (NDAs) to ...
Cytokinetics, Incorporated (CYTK) is gearing up to complete its rolling NDA submission of aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy [oHCM] in Q3 of 2024.
Singh maintained guidance that "we'll see top line results released before the end of this calendar quarter, so by the end of this calendar year" for PALISADE-3. Singh projected that top line results ...
TOKUSHIMA, Japan--(BUSINESS WIRE)--150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, ...
On-track progress for the New Drug Application (NDA) for paltusotine, with a PDUFA target action date set for September 25, 2025, indicating strong engagement with the FDA. Marketing authorization ...
TUCSON, Ariz. (KVOA) - Tucson City Council is set to discuss potential reforms to the city's use of non-disclosure agreements (NDAs) in an upcoming study session. The Tucson City Council study session ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results